A sound-conducting biological tympanic membrane repair material and preparation method thereof

Acoustic conductive biological tympanic membrane repair material prepared through electrospinning process, combined with drug-modified gelatin, solves the problems of poor tensile resistance and infection risk of existing materials, achieves rapid healing of the tympanic membrane and hearing recovery, and meets the clinical large-area defects repair requirements.

CN118718095BActive Publication Date: 2024-11-29NUOYIMEIER (SHANDONG) MEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411230307.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-29
Estimated Expiration
2044-09-04

AI Technical Summary

Technical Problem

The existing tympanic membrane repair materials have poor tensile resistance, are not easy to degrade, have the risk of infection and cannot restore the original transparent state, which is difficult to meet the rapid healing needs of large-area tympanic membrane defects in clinical large-area.

Method used

Acoustic conductive biotyping membrane repair material is prepared by electrospinning technology, and loose structures suitable for cell adhesion are formed through three-stage voltage control of gelatin spinning membrane, and drug-modified gelatin can achieve continuous drug release, satisfying mechanical properties and biological fusion. Sexual requirements.

Benefits of technology

The tensile strength and biomodulus of the tympanic membrane repair material are achieved, which promotes cell adhesion and growth, ensures hearing recovery and healing effect, while avoiding the risk of infection, and meeting the degradation cycle needs of 2-3 months.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118718095B_ABST
    Figure CN118718095B_ABST
Patent Text Reader

Abstract

The invention discloses a sound-conducting biological tympanic membrane repair material and a preparation method thereof, and relates to the technical field of tympanic membrane repair. The method comprises the following steps: providing a gelatin spinning solution and a cross-linking solution, and forming a spun fiber membrane through an electrostatic spinning process; wherein the spun fiber membrane has a thickness of 50-400 μm, a cross-linking degree of 60%-90%, and a resonance frequency of 220 Hz-600 Hz; wherein the gelatin can be drug-modified gelatin, and the method can further adjust the electrostatic spinning voltage so that the prepared sound-conducting biological tympanic membrane repair material has both mechanical properties, repair properties and acoustic conduction properties required for tympanic membrane repair, on the one hand, has tensile strength and biomodulus that meet the use requirements of tympanic membrane repair, and ensures the availability and tensile resistance of surgical operations; on the other hand, by designing the resonance frequency range of the biological tympanic membrane, the postoperative hearing effect can be maximized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to an eardrum repair material, and in particular to a sound-conducting biological eardrum repair material and a preparation method thereof. Background Art

[0002] The tympanic membrane is located between the external auditory canal and the tympanic cavity. It is the outer wall of the tympanic cavity, making the tympanic cavity a closed middle ear cavity. The tympanic membrane is composed of the epithelium, fibrous layer, and mucosa layer from the outside to the inside. The tympanic membrane of an adult is about 9 mm high, 8 mm wide, and 0.1 mm thick. Because the tympanic membrane itself is thin and close to the outside world, tympanic membrane perforation is relatively common in clinical practice. Its causes are mostly acute and chronic otitis media, iatrogenic injury, pressure injury, tympanic tube stoma, etc.

[0003] After the eardrum is perforated, external pollutants will enter the middle ear through the perforation and cause infection and pus. Tinnitus, ear pain, and hearing loss are the main clinical manifestations of eardrum perforation. A perforated eardrum will reduce the effective vibration area of ​​the eardrum and weaken the energy of the sound waves transmitted from the outside, thus causing a decrease in hearing ability. Clinically, 90% of eardrum perforations can recover on their own, but larger eardrum perforations cannot heal naturally. Currently, autologous tissue is used for repair in clinical practice, and the repair time for eardrum perforations is about 2-3 months.

[0004] Temporalis fascia is the most commonly used material for tympanic membrane repair and is the gold standard for clinical tympanic membrane repair. However, the use of temporalis fascia repair not only requires the opening of a secondary surgical area and secondary trauma, but also has limited material availability. In addition, because the tympanic membrane is exposed to the external auditory canal, no matter what repair material is used, there is a risk of surgical failure due to secondary infection. In addition, if autologous tissues such as cartilage and temporalis fascia are used, the position of the tympanic membrane cannot return to its original transparent state after the tympanic membrane repair heals, which is not conducive to later endoscopic diagnosis of the ear.

[0005] Therefore, there is an urgent need in clinical practice for an artificial tympanic membrane repair material that can replace autologous tissue, is biodegradable, has good repairability, good tensile strength, good postoperative hearing recovery effect, and long-term drug continuous release function during the repair period. Summary of the invention

[0006] In view of the above problems existing in the tympanic membrane repair materials in the prior art, the present invention provides a sound-conducting biological tympanic membrane repair material and a preparation method thereof.

[0007] In one aspect, the present invention provides a method for preparing a sound-conducting biological tympanic membrane repair material, the method comprising the following steps:

[0008] providing a spinning solution and a cross-linking solution, wherein the spinning solution comprises gelatin;

[0009] The spinning solution and the cross-linking solution are formed into a spinning fiber membrane through an electrostatic spinning process;

[0010] The spun fiber membrane has a thickness of 50-400 μm, a cross-linking degree of 60%-90%, and a resonance frequency of 220 Hz-600 Hz.

[0011] In some embodiments of the present invention, the resonance frequency of the spun fiber membrane is 450 Hz-600 Hz.

[0012] In some embodiments of the present invention, the elastic modulus of the spun fiber membrane is 19.2-45.3 Mpa, and the tensile strength is 1.8-3.6 Mpa.

[0013] In some embodiments of the present invention, the elastic modulus of the spun fiber membrane is 35-40 MPa and the tensile strength is 2.5-3.1 MPa.

[0014] In some embodiments of the present invention, the electrospinning includes an initial spinning section, a middle spinning section, and a final spinning section, wherein the middle spinning section is between the initial spinning section and the final spinning section.

[0015] In the initial stage of spinning, spinning is performed at a first spinning voltage to form a first fiber accumulation layer;

[0016] In the middle stage of spinning, spinning is performed at a second spinning voltage to form a second fiber accumulation layer on the first fiber accumulation layer;

[0017] In the final stage of spinning, spinning is performed at a third spinning voltage to form a third fiber accumulation layer on the second fiber accumulation layer;

[0018] in,

[0019] The first spinning voltage is less than the second spinning voltage, and the second spinning voltage is less than the third spinning voltage;

[0020] The initial spinning time is shorter than the middle spinning time, and the final spinning time is shorter than the middle spinning time.

[0021] In some embodiments of the present invention, the first fiber stacking layer has a loose fiber structure suitable for separation from the electrospinning receiving device; the second fiber stacking layer has a fiber structure with sufficient tensile properties; and the third fiber stacking layer has a porous structure suitable for the adhesion and growth of epithelial cells and mucosal cells.

[0022] In some embodiments of the present invention, the first spinning voltage is 45-55 kV, the second spinning voltage is 55-60 kV, and the third spinning voltage is 60-65 kV.

[0023] In some embodiments of the present invention, the initial spinning time is 0.2-0.8 h, the middle spinning time is 4.5-7 h, and the final spinning time is 0.2-0.8 h.

[0024] In some embodiments of the present invention, the spinning humidity is 40±10% to 60±10%, and the rotation speed is 60-200 rpm.

[0025] In some embodiments of the present invention, gelatin is used as the spinning raw material, and the content of gelatin in the spinning solution is 10% w / v-35% w / v.

[0026] In some embodiments of the present invention, glyoxal is used as a cross-linking agent to prepare a glyoxal cross-linking solution with a concentration ranging from 2%wt to 20%wt.

[0027] In some embodiments of the present invention, the gelatin is drug-modified gelatin, and the preparation of the drug-modified gelatin includes: chlorination treatment of the drug to form a chlorination reaction and then mixing it with gelatin to form the drug-modified gelatin.

[0028] In some embodiments of the present invention, the chlorination treatment is to react the drug with thionyl chloride.

[0029] In some embodiments of the present invention, the drug is selected from one or more of the following drugs: levofloxacin, ofloxacin, norfloxacin, pefloxacin, enoxacin and ciprofloxacin.

[0030] In some embodiments of the present invention, the drug is chlorinated and then linked to gelatin via an ester bond to form drug-modified gelatin.

[0031] In some embodiments of the present invention, the drug is ciprofloxacin, and the content of gelatin-ciprofloxacin (GEL-CiFX) in the drug-modified gelatin spinning solution is 10% w / v-35% w / v.

[0032] In some embodiments of the present invention, the preparation of the drug-modified gelatin includes: forming a solution with gelatin GEL, chloroacylated ciprofloxacin CiFX-COCl and a solvent thereof, wherein the content of GEL is 10% w / v-35% w / v, and the content of chloroacylated ciprofloxacin is 3% w / v-10.5% w / v.

[0033] In some embodiments of the present invention, in the drug-modified gelatin, the grafting rate of the drug ciprofloxacin is 80%-95%.

[0034] In some embodiments of the present invention, the repair material degrades within 2-3 months, which matches the time required for the clinical healing of large-area tympanic membrane defects.

[0035] On the other hand, the present invention provides a sound-conducting biological tympanic membrane repair material obtained according to the above preparation method.

[0036] Compared with the prior art, the present invention has the following beneficial technical effects:

[0037] (1) The sound-conducting biological tympanic membrane repair material of the present invention has the mechanical properties, repair properties and acoustic conduction properties required for tympanic membrane repair. On the one hand, it has the tensile strength and biomodulus that meet the requirements for tympanic membrane repair, ensuring the usability and tensile strength of surgical operations. On the other hand, by designing the resonance frequency range of the biological tympanic membrane, the postoperative hearing effect can be maximized.

[0038] (2) The sound-conducting biological tympanic membrane repair material of the present invention further regulates the spinning process so that the stacking structure of the spun fibers can provide the tensile strength required for tympanic membrane perforation repair, and is not prone to deformation and contracture during the implantation process; a loose structure is constructed by using high-voltage spinning at the final stage of spinning to form a large number of fiber stacks, providing cell adhesion sites and space, which is conducive to the adhesion and growth of epithelial cells and mucosal cells at the tympanic membrane perforation site, thereby having excellent bio-integration, ensuring the tympanic membrane regeneration and healing effect, and at the same time, tissue growth avoids material displacement.

[0039] (3) The spinning raw material gelatin of the sound-conducting biological tympanic membrane repair material of the present invention contains RGD sequence, which can specifically bind to a variety of cell integrins, provide cell adhesion sites, promote the adhesion and aggregation of epithelial cells and mucosal cells at the tympanic membrane perforation site, and facilitate the repair of perforated tympanic membrane. In addition, the degradation cycle of the repair material meets the clinical requirement of 2-3 months for the healing of large-area tympanic membrane defects.

[0040] (4) When the spinning raw material of the sound-conducting biological tympanic membrane repair material of the present invention uses drug-modified gelatin, drug grafting is achieved through ester bond connection, so that the biological tympanic membrane has the function of sustained drug release during repair. In addition, drug grafting is achieved by grafting with the hydroxyl group of hydroxyproline in gelatin, which not only avoids the cell adhesion site of the RGD sequence that does not affect the perforation repair process, but also provides sustained drug release during the repair period, plays an antibacterial and anti-infection role, and solves the problem of recurrence of inflammation at the perforation site and repair failure caused by infection of the autologous repair material. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 It is a scanning electron microscope image of a cross section formed by cutting the sound-conducting biological tympanic membrane repair material of Example 8 of the present invention along the membrane thickness direction.

[0042] Figure 2 This is a HE staining image observed in a cell migration experiment of the sound-conducting biological eardrum repair material of Examples 1-5 of the present invention.

[0043] Figure 3 The graph shows the degradation of the sound-conducting biological tympanic membrane repair material of Example 8 of the present invention observed after the rats were killed 1 week, 4 weeks, 8 weeks, 10 weeks and 12 weeks after being implanted subcutaneously.

[0044] Figure 4 This is a graph showing the in vivo drug release curve of the sound-conducting biological tympanic membrane repair material of Example 8 of the present invention.

[0045] Figure 5a This is a microscopic photograph of the perforation model created during surgery in a guinea pig tympanic membrane repair experiment.

[0046] Figure 5b This is a microscopic photograph of the biological tympanic membrane repair during surgery in a guinea pig tympanic membrane repair experiment.

[0047] Figure 5c This is a microscopic photograph of the guinea pig tympanic membrane repair effect 12 weeks after surgery.

[0048] Figure 6 This is a HE staining picture of the sound-conducting biological tympanic membrane repair material of Example 8 of the present invention after the tympanic membrane of a guinea pig has healed 12 weeks after the repair surgery. DETAILED DESCRIPTION

[0049] Various aspects of the present invention will be described in detail below in conjunction with specific embodiments. These specific embodiments are only used to illustrate the present invention and do not constitute any limitation on the protection scope of the present invention.

[0050] In a specific embodiment of the present invention, in order to meet the acoustic conduction requirements of biological tympanic membrane repair materials, the resonant frequency is designed to be 220Hz-600Hz, so as to meet the requirements of artificial tympanic membrane for postoperative hearing improvement. When the resonant frequency of the biological tympanic membrane of the present invention reaches 450Hz-600Hz, the hearing recovery effect in the postoperative repair period of tympanic membrane perforation is better, and it is particularly suitable as a sound conduction tympanic membrane repair material. The control of electrospinning process parameters can achieve the regulation of the resonant frequency of the biological tympanic membrane, improve the hearing after tympanic membrane repair, and effectively ensure the hearing improvement effect after recovery.

[0051] In a specific embodiment of the present invention, in order to meet the mechanical properties of biological tympanic membrane repair materials, the elastic modulus of the repair material is adjusted to 19.2-45.3Mpa, and the tensile strength is adjusted to 1.8-3.6Mpa. In order to better balance the repair properties such as cell adhesion and migration, the elastic modulus of the biological tympanic membrane can be further adjusted to 35-40Mpa, and the tensile strength can be further adjusted to 2.5-3.1Mpa. In this case, it can provide mechanical performance support that meets the needs of tympanic membrane repair while ensuring cell climbing, achieving a balance between mechanical support performance and repair performance.

[0052] In a specific embodiment of the present invention, in order to better balance the mechanical support performance and the repair performance, the electrospinning process parameters can be regulated. For example, in some embodiments, the stacking structure of the fibers during the spinning process is regulated through three-stage voltage control to construct a biological tympanic membrane with both mechanical properties and repair properties. In the initial stage of spinning, a lower voltage (i.e., the first voltage) is first used for initial spinning to control a lower fiber amount and ensure that the solvent is fully volatilized, thereby constructing a loose fiber stacking to form a first fiber stacking layer, which is also beneficial for separating the membrane material from the receiving device; then, the voltage (i.e., the second voltage) is gradually increased for mid-spinning, and a higher fiber amount and dense fiber stacking are controlled in the middle stage of spinning to form a second fiber stacking layer. This process control can make the mechanical properties of the biological tympanic membrane better, effectively prevent the postoperative retraction of the perforation site, and help resist the negative pressure of the middle ear; then, the voltage is increased again (i.e., the third voltage) for final spinning. In the final stage of spinning, a high voltage is used to form a fiber stacking to form a larger porosity, i.e., form a third fiber stacking layer, thereby providing cell adhesion sites and space, which is beneficial for the adhesion of epithelial cells and mucosal cells at the tympanic membrane perforation site, and promotes the repair and healing of the perforation site.

[0053] In a specific embodiment of the present invention, the spinning raw material of the biological eardrum is gelatin or drug-modified gelatin, and the cross-linking agent is glyoxal. The cross-linking agent may also be other cross-linking agents, for example, one or a combination of glyoxal, glutaraldehyde, and formaldehyde. In addition, the degradation cycle of the biological eardrum is regulated by controlling the degree of cross-linking to meet the clinical degradation requirement of 2-3 months for the healing of large-area eardrum defects. The degree of cross-linking of the biological eardrum of the present invention can be controlled at 50%-90%. For example, the degree of cross-linking of the biological eardrum in the embodiment of the present invention is controlled at 60%-90%.

[0054] In a specific embodiment of the present invention, the drug in the drug-modified gelatin is ciprofloxacin, and other drugs may also be selected, such as levofloxacin, ofloxacin, norfloxacin, pefloxacin, or enoxacin. The drug is continuously released during the tympanic membrane repair process to play an antibacterial and anti-infection role, thereby solving the problem of recurrence of inflammation at the perforation site and repair failure caused by infection of the autologous repair material.

[0055] In a specific embodiment of the present invention, the spinning raw material gelatin has an RGD sequence, which can promote the adhesion and aggregation of epithelial cells and mucosal cells at the site of tympanic membrane perforation. Through ester bond connection, drug grafting is achieved and the cell adhesion site where the RGD sequence does not affect the perforation repair process is avoided. At the same time, it also provides continuous sustained release of drugs during tympanic membrane repair, so that the biological tympanic membrane has the function of continuous drug release, thereby achieving a long-term anti-inflammatory effect.

[0056] Example 1

[0057] The acoustic conductive tympanic membrane repair material of this embodiment is prepared by an electrospinning process, which includes the following steps:

[0058] (1) Forming a gelatin spinning solution: Weigh gelatin (GEL), add a water-acetic acid-ethyl acetate mixed solvent, stir and dissolve, and obtain a gelatin spinning solution; wherein the mass volume ratio of GEL is 10% w / v;

[0059] (2) Weigh glyoxal and dissolve it in water to form a glyoxal solution with a concentration of 2%wt;

[0060] (3) GEL spinning solution and glyoxal solution were cross-linked in real time with a flow rate ratio of 60:1;

[0061] (4) Electrospinning was performed under the following conditions: humidity range 40±10%, rotation speed 60 rpm; spinning voltage was adjusted in three stages, the initial stage, middle stage and final stage of spinning were gradually increased from 45 kV, 55 kV and 60 kV, respectively; the spinning time in the initial stage, middle stage and final stage of spinning were 0.2 h, 2 h and 0.8 h, respectively; the thickness of the biofiber membrane formed by spinning was 50 μm;

[0062] (5) The spun fiber membrane obtained in step (4) was cross-linked at 80°C and vacuum treated for 24 hours to obtain a biological eardrum membrane with a cross-linking degree of 60%.

[0063] Example 2

[0064] The acoustic conductive tympanic membrane repair material of this embodiment is prepared by an electrospinning process, which includes the following steps:

[0065] (1) Forming a gelatin spinning solution: weighing GEL, adding a water-acetic acid-ethyl acetate mixed solvent, stirring and dissolving, and obtaining a gelatin spinning solution; wherein the mass volume ratio of GEL is 35% w / v;

[0066] (2) Weigh glyoxal and dissolve it in water to form a glyoxal solution with a concentration of 20%wt;

[0067] (3) GEL spinning solution and glyoxal solution were cross-linked in real time with a flow rate ratio of 45:1;

[0068] (4) Electrospinning was performed under the following conditions: humidity range was 60±10%, rotation speed was 200 rpm, voltage was adjusted in three stages, the voltage was gradually increased from 55 kV, 60 kV, and 65 kV in the initial stage, middle stage, and final stage of spinning, respectively; the spinning time in the initial stage, middle stage, and final stage of spinning was 0.8 h, 7 h, and 0.2 h, respectively; the thickness of the biofiber membrane formed by spinning was 400 μm;

[0069] (5) The spun fiber membrane obtained in step (4) was cross-linked at 80°C and vacuum treated for 24 hours to obtain a biological eardrum membrane with a cross-linking degree of 90%.

[0070] Example 3

[0071] The acoustic conductive tympanic membrane repair material of this embodiment is prepared by an electrospinning process, which includes the following steps:

[0072] (1) Forming a gelatin spinning solution: weighing GEL, adding a water-acetic acid-ethyl acetate mixed solvent, stirring and dissolving, and obtaining a spinning solution; wherein the mass volume ratio of GEL is 20% w / v;

[0073] (2) Weigh glyoxal and dissolve it in water to form a glyoxal solution with a concentration of 15%wt;

[0074] (3) GEL spinning solution and glyoxal solution were cross-linked in real time with a flow rate ratio of 40:1;

[0075] (4) Electrospinning was performed under the following conditions: humidity range was 50±10%, rotation speed was 180 rpm, voltage was adjusted in three stages, the voltage at the initial stage, the middle stage, and the final stage of spinning gradually increased from 51 kV, 58 kV, and 61 kV, respectively; the spinning time at the initial stage, the middle stage, and the final stage of spinning was 0.3 h, 6.5 h, and 0.4 h, respectively; the thickness of the biofiber membrane formed by spinning was 200 μm;

[0076] (5) The spun fiber membrane obtained in step (4) was cross-linked at 80°C and vacuum treated for 24 hours to obtain a biological eardrum membrane with a cross-linking degree of 85%.

[0077] Example 4

[0078] The acoustic conductive tympanic membrane repair material of this embodiment is prepared by an electrospinning process, which includes the following steps:

[0079] (1) Forming a gelatin spinning solution: weighing GEL, adding a water-acetic acid-ethyl acetate mixed solvent, stirring and dissolving, and obtaining a spinning solution; wherein the mass volume ratio of GEL is 20% w / v;

[0080] (2) Weigh glyoxal and dissolve it in water to form a glyoxal solution with a concentration of 15%wt;

[0081] (3) GEL spinning solution and glyoxal solution were cross-linked in real time with a flow rate ratio of 40:1;

[0082] (4) Electrospinning was performed under the following conditions: humidity range was 50±10%, rotation speed was 180 rpm, voltage was adjusted in three stages, the voltage was gradually increased from 51 kV, 55 kV, and 61 kV in the initial stage, middle stage, and final stage of spinning, respectively; the spinning time in the initial stage, middle stage, and final stage of spinning was 0.3 h, 4.5 h, and 0.3 h, respectively; the thickness of the biofiber membrane formed by spinning was 150 μm;

[0083] (5) The spun fiber membrane obtained in step (4) was cross-linked at 80°C and vacuum treated for 24 hours to obtain a biological eardrum membrane with a cross-linking degree of 85%.

[0084] Example 5

[0085] The acoustic conductive tympanic membrane repair material of this embodiment is prepared by an electrospinning process, which includes the following steps:

[0086] (1) Forming a gelatin spinning solution: weighing GEL, adding a water-acetic acid-ethyl acetate mixed solvent, stirring and dissolving, and obtaining a spinning solution; wherein the mass volume ratio of GEL is 20% w / v;

[0087] (2) Weigh glyoxal and dissolve it in water to form a glyoxal solution with a concentration of 15%wt;

[0088] (3) GEL spinning solution and glyoxal solution were cross-linked in real time with a flow rate ratio of 40:1;

[0089] (4) Electrospinning was performed under the following conditions: humidity range was 50±10%, rotation speed was 180 rpm, voltage was adjusted in three stages, the voltage was gradually increased from 51 kV, 60 kV, and 61 kV in the initial stage, middle stage, and final stage of spinning, respectively; the spinning time in the initial stage, middle stage, and final stage of spinning was 0.3 h, 6 h, and 0.2 h, respectively; the thickness of the spinning fiber membrane layer formed by spinning was 350 μm;

[0090] (5) The spun fiber membrane obtained in step (4) was cross-linked at 80°C and vacuum treated for 24 hours to obtain a biological eardrum membrane with a cross-linking degree of 85%.

[0091] Example 6

[0092] In this embodiment, GEL is subjected to drug modification treatment on the basis of embodiment 3. The preparation of the sound-conducting tympanic membrane repair material in this embodiment includes the following steps:

[0093] (1) Drug chlorination treatment: Weigh 1 g of ciprofloxacin (CiFX), add 400 mL of a mixture of SOCl2 and THF, heat to 80°C and reflux for 4-6 hours, then perform rotary evaporation, sedimentation, and drying to obtain chlorinated ciprofloxacin (CiFX-COCl);

[0094] (2) Forming drug-modified gelatin: Weigh gelatin (GEL) and CiFX-COCl and dissolve them in acetic acid solution, adjust the pH to <5 and continue stirring, dialyze, freeze-dry and pulverize to obtain drug-modified gelatin (GEL-CiFX); wherein the mass volume ratio of GEL is 10% w / v, and the mass volume ratio of CiFX-COCl is 3% w / v; the drug grafting rate of GEL-CiFX is 80%;

[0095] (3) Forming a drug-modified gelatin spinning solution: weigh GEL-CiFX, add a water-acetic acid-ethyl acetate mixed solvent, stir and dissolve, and obtain a spinning solution, wherein the mass volume ratio of GEL-CiFX is 20% w / v;

[0096] (4) Weigh glyoxal and dissolve it in water to form a glyoxal solution with a concentration of 15%wt;

[0097] (5) GEL-CiFX spinning solution and glyoxal solution were cross-linked in real time with a flow rate ratio of 40:1;

[0098] (6) Performing electrospinning: The electrospinning conditions are as follows: humidity range is 50±10%, rotation speed is 180 rpm, and voltage is adjusted in three stages. Specifically, the voltage is gradually increased from 51 kV, 58 kV, and 61 kV in the initial stage, middle stage, and final stage of spinning, respectively. The spinning time in the initial stage, middle stage, and final stage of spinning is 0.3 h, 6.5 h, and 0.4 h, respectively. The thickness of the spinning fiber membrane layer formed by spinning is 200 μm.

[0099] (7) The spun fiber membrane obtained in step (6) was cross-linked at 80°C and vacuum treated for 24 hours to obtain a biological eardrum membrane with a cross-linking degree of 85%.

[0100] Example 7

[0101] In this embodiment, GEL is subjected to drug modification treatment on the basis of embodiment 3. The preparation of the sound-conducting tympanic membrane repair material in this embodiment includes the following steps:

[0102] (1) Drug chlorination treatment: Weigh 1 g of ciprofloxacin (CiFX), add 400 mL of a mixture of SOCl2 and THF, heat to 80 °C and reflux for 4-6 h, then perform rotary evaporation, sedimentation, and drying to obtain chlorinated ciprofloxacin (CiFX-COCl);

[0103] (2) Forming drug-modified gelatin: Weigh gelatin (GEL) and CiFX-COCl and dissolve them in acetic acid solution, adjust the pH to <5, continue stirring, dialyze, freeze-dry, and pulverize to obtain drug-modified gelatin (GEL-CiFX); wherein the mass volume ratio of GEL is 35% w / v, and the mass volume ratio of CiFX-COCl is 10.5 w / v; the drug grafting rate of GEL-CiFX is 95%;

[0104] (3) Forming a drug-modified gelatin spinning solution: weigh GEL-CiFX, add a water-acetic acid-ethyl acetate mixed solvent, stir and dissolve, and obtain a spinning solution; wherein the mass volume ratio of GEL-CiFX is 20% w / v;

[0105] (4) Weigh glyoxal and dissolve it in water to form a glyoxal solution with a concentration of 15%wt;

[0106] (5) GEL-CiFX spinning solution and glyoxal solution were cross-linked in real time with a flow rate ratio of 40:1;

[0107] (6) Performing electrospinning: The electrospinning conditions are as follows: humidity range is 50±10%, rotation speed is 180 rpm, and voltage is adjusted in three stages. Specifically, the voltage is gradually increased from 51 kV, 58 kV, and 61 kV in the initial stage, middle stage, and final stage of spinning, respectively. The spinning time in the initial stage, middle stage, and final stage of spinning is 0.3 h, 6.5 h, and 0.4 h, respectively. The thickness of the spinning fiber membrane layer formed by spinning is 200 μm.

[0108] (7) The spun fiber membrane obtained in step (6) was cross-linked at 80°C and vacuum treated for 24 hours to obtain a biological eardrum membrane with a cross-linking degree of 85%.

[0109] Example 8

[0110] In this embodiment, GEL is subjected to drug modification treatment on the basis of embodiment 3. The preparation of the sound-conducting tympanic membrane repair material in this embodiment includes the following steps:

[0111] (1) Drug chlorination treatment: Weigh 1 g of ciprofloxacin (CiFX), add 400 mL of a mixture of SOCl2 and THF, heat to 80°C and reflux for 4-6 hours, then perform rotary evaporation, sedimentation, and drying to obtain chlorinated ciprofloxacin (CiFX-COCl);

[0112] (2) Forming drug-modified gelatin: Weigh gelatin (GEL) and CiFX-COCl and dissolve them in acetic acid solution, adjust the pH to <5, continue stirring, dialyze, freeze-dry and pulverize to obtain drug-modified gelatin (GEL-CiFX); wherein the mass volume ratio of GEL is 25% w / v, and the mass volume ratio of CiFX-COCl is 6.9 w / v; the drug grafting rate of GEL-CiFX is 90%;

[0113] (3) Forming a drug-modified gelatin spinning solution: weigh GEL-CiFX, add a water-acetic acid-ethyl acetate mixed solvent, stir and dissolve, and obtain a spinning solution; wherein the mass volume ratio of GEL-CiFX is 20% w / v;

[0114] (4) Weigh glyoxal and dissolve it in water to form a glyoxal solution with a concentration range of 15%wt;

[0115] (5) GEL-CiFX spinning solution and glyoxal solution were cross-linked in real time with a flow rate ratio of 40:1;

[0116] (6) Performing electrospinning: The electrospinning conditions are as follows: humidity range is 50±10%, rotation speed is 180 rpm, and voltage is adjusted in three stages. Specifically, the voltage is gradually increased from 51 kV, 58 kV, and 61 kV in the initial stage, middle stage, and final stage of spinning, respectively. The spinning time in the initial stage, middle stage, and final stage of spinning is 0.3 h, 6.5 h, and 0.4 h, respectively. The thickness of the spinning fiber membrane layer formed by spinning is 200 μm.

[0117] (7) The spun fiber membrane obtained in step (6) was cross-linked at 80°C and vacuum treated for 24 hours to obtain a biological eardrum membrane with a cross-linking degree of 85%.

[0118] In order to further illustrate the beneficial technical effects of the sound-conducting biological tympanic membrane repair material of the present invention, the physical and chemical property test data of the sound-conducting biological tympanic membrane repair material prepared according to a specific embodiment of the present invention will be specifically described below.

[0119] 1. Scanning electron microscopy observation

[0120] The cross section of the biological tympanic membrane prepared in Example 8 was observed by scanning electron microscopy along the membrane thickness direction. The SEM image observed is as follows: Figure 1 As shown in the figure, it can be observed from the scanning electron microscope that the biological tympanic membrane has differences in fiber stacking, which can effectively guide the growth of epithelial and mucosal cells while providing the tensile strength required for tympanic membrane repair, playing a role in anti-curling and sound conduction.

[0121] 2. Resonance frequency and hearing test 2 weeks after surgery

[0122] The resonance frequency of the biological eardrum prepared in Examples 1-8 was tested using a Doppler vibrometer, and the postoperative hearing of the biological eardrum under short-term repair was tested through an animal experiment 2 weeks after surgery. The specific experimental method is as follows:

[0123] 24 guinea pigs were made into left tympanic membrane perforation models, and the tympanic membrane was perforated using a CO2 laser. The biological tympanic membranes prepared in Examples 1-8 were cut into appropriate sizes for the surgical area for repair. After surgery, 1% lidocaine was injected locally into the ears of the mice for analgesia. The tympanic cavity was not filled with sponge to ensure that the tympanic cavity had a cavity, which was convenient for hearing testing 2 weeks after surgery. Auditory brainstem response (ABR) tests were performed before modeling, after modeling, and 2 weeks after surgery, and the results are shown in Table 1.

[0124] Table 1. Resonance frequency test data of biological eardrums of Examples 1-8 and hearing test results during the repair process

[0125]

[0126] It can be seen from the resonance frequency test data that the resonance frequency of the biological eardrum prepared in Examples 1-8 is between 220 Hz and 600 Hz, which can meet the requirements of artificial eardrum for postoperative hearing improvement. When the resonance frequency of the biological eardrum of the present invention reaches 450 Hz to 600 Hz, the hearing recovery effect is good within a shorter repair period, and it is particularly suitable as a sound conduction eardrum repair material.

[0127] 3. Cell Migration Assay

[0128] The biological tympanic membrane prepared in Experimental Example 1-5 was subjected to a cell migration experiment. The biological tympanic membrane prepared in Experimental Example 1-5 was cut into disc samples with a diameter of 20 mm and placed in sterile PBS for hydration for 30 seconds. An appropriate amount of culture medium was added and placed in a cell culture incubator for incubation for 2 hours. The culture medium was aspirated and rinsed twice with PBS. L929 fibroblasts were inoculated onto the material and placed in a cell culture incubator for incubation for 30 minutes. The culture plate was taken out and an appropriate amount of complete culture medium was added and placed in a cell culture incubator for culture. The culture conditions were 37°C, 5% CO2, and 95% humidity. The complete culture medium was replaced every 48 hours. After culturing for 14 days, the material was fixed with 4% paraformaldehyde fixative for 2 hours, embedded and sectioned, and HE staining was performed. The results are as follows Figure 2 As shown. The results show that the biological eardrums prepared in Examples 1-5 all have a loose surface structure that is conducive to the inward attachment and climbing of cells. It can be seen that by adjusting the spinning end voltage to a high voltage to form a large number of fiber stacks and controlling the corresponding spinning end time, the loose pore structure on the membrane surface can be regulated, thereby obtaining a loose surface structure that is conducive to the inward attachment and climbing of cells.

[0129] 4. Mechanical properties test

[0130] The tensile strength and elastic modulus of the membrane materials of Examples 1-8 were tested using an electronic universal testing machine at a rate of 50 mm / min and a sample size of 15 mm×50 mm. The test results are shown in Table 2. According to the mechanical property test data, the elastic modulus of the biological tympanic membranes of Examples 1-8 is between 19.2-45.3 Mpa, and the tensile strength is between 1.8-3.6 Mpa. Combined with the above-mentioned cell migration experimental results, it can be seen that when the elastic modulus of the biological tympanic membrane of the present invention reaches 35-40 Mpa and the tensile strength reaches 2.5-3.1 Mpa, this biological tympanic membrane can provide better mechanical performance support while ensuring cell climbing, satisfying the balance between mechanical support performance and repair performance.

[0131] Table 2. Summary of mechanical properties test data

[0132]

[0133] 5. Test on the change of the number of ε-amino groups in the side chain of gelatin protein peptide chain

[0134] The drug-modified gelatin GEL-CiFX prepared by steps (1) to (4) of Examples 6, 7, and 8, respectively, was measured by the TNBS (2,4,6-trinitrobenzenesulfonic acid) method to determine the change in the number of side chain ε-amino groups in the gelatin protein peptide chain.

[0135] The ε-amino group content is calculated as follows, in mol / g:

[0136]

[0137] Where, A - absorption value; 1.46×10 4 - molar absorption coefficient of trinitrobenzene derivatives; b - optical path, unit: cm; X - sample weight, unit: g;

[0138] Table 3. Number of amino groups on the surface of gelatin and drug-modified gelatin of Examples 6-8

[0139]

[0140] As shown in Table 3, there is no significant change in the number of amino groups on the surface of gelatin after drug grafting. Gelatin contains RGD sequences, which can specifically bind to a variety of cell integrins, provide cell adhesion sites, promote the adhesion and aggregation of epithelial cells and mucosal cells at the perforation site, and facilitate the repair of perforated tympanic membranes. Drug grafting not only avoids the cell adhesion sites of the RGD sequence that do not affect the perforation repair process, but also provides a growth scaffold for epithelial cells and mucosal cells, and at the same time can maintain drug release during the tympanic membrane repair period, achieving a long-term anti-inflammatory effect during postoperative tympanic membrane repair.

[0141] 6. In vivo degradation and drug release performance testing

[0142] Based on the above experimental test results, the biological tympanic membrane sample of Example 8 was selected, and 15 rats were taken for subcutaneous implantation test to test the degradation cycle and drug release performance of the biological tympanic membrane in vivo. The animals were killed for observation at 1 week, 4 weeks, 8 weeks, 10 weeks and 12 weeks after implantation. After the animal was anesthetized, the dorsal hair on both sides of the experimental spine was removed, and subcutaneous implantation was performed at about 2 cm from the spine on both sides of the midline of the rat spine, for a total of 4 sites. The size of the test sample was 10mm×10mm, the implantation amount was 1 piece / site, and the interval between the two adjacent sites on the same side was at least 1 cm. After the implantation was completed, iodine disinfection was performed. Figure 3 The images are shown in Figure 1, 4, 8, 10, and 12 weeks after the biotympanic membrane was implanted subcutaneously in rats. Figure 3 As shown, a small amount of debris can be observed remaining after 12 weeks of implantation in vivo, indicating that this biological tympanic membrane material can maintain a degradation cycle of 2-3 months, providing support for epithelial cells and mucosal cells while inducing cell climbing to facilitate the repair of the perforation site.

[0143] The incompletely degraded biological tympanic membrane was placed in 30 ml acetonitrile solution and ultrasonicated for 20 min. The drug release behavior was tested by liquid phase. The in vivo drug release curve was as follows: Figure 4 The drug release results show that chemically connecting drug molecules to gelatin can effectively prolong the drug release cycle and achieve continuous release of drugs at the perforation site to inhibit bacteria and inflammation during the repair period.

[0144] 7. Tympanic membrane repair and hearing recovery test

[0145] 45 guinea pigs were made into left tympanic membrane perforation models. The tympanic membrane was perforated using a CO2 laser. The biological tympanic membrane was cut into a suitable size for the surgical area for repair experiments. The experimental process was as follows: Figure 5a to Figure 5c (Experimental Group 2) shows that, Figure 5a This is a microscope photo of the perforation model during the guinea pig tympanic membrane repair experiment. Figure 5b This is a microscopic photo of a biological tympanic membrane repair during a guinea pig tympanic membrane repair experiment. Figure 5c This is a microscopic photo of the tympanic membrane repair effect of the guinea pig tympanic membrane repair experiment 12 weeks after surgery. After surgery, 1% lidocaine was injected locally into the mouse ear for analgesia. The changes in the tympanic membrane were observed under a microscope 12 weeks after surgery and the healing rate of the tympanic membrane perforation was calculated (the healing area of ​​the perforation site was > 99%). The healing rate of each group was tested by chi-square test, indicating that the difference in healing rate between the two groups was significant (P < 0.01). The results are shown in Table 4:

[0146] Table 4. Tympanic membrane healing rate results

[0147]

[0148] Hearing tests were performed on the tympanic membrane before and after modeling, and the results are shown in Table 5. The average hearing of the blank control group increased by 5.2 dB 12 weeks after surgery; the average hearing of the experimental group 1 increased by 10.6 dB 12 weeks after surgery, which was 1.03 times higher than that of the blank control group; the average hearing of the experimental group 2 increased by 15.4 dB 12 weeks after surgery, which was 1.96 times higher than that of the blank control group. Therefore, the hearing recovery effect after repairing tympanic membrane perforation using this sound-conducting biological tympanic membrane is better than that of the blank control group, indicating that this biological tympanic membrane has good postoperative sound conduction recovery performance.

[0149] The auditory brainstem response (ABR) test was used to test the hearing of the tympanic membrane that had been repaired and healed in animal experiments. The results are shown in Table 5. Compared with the blank control group, the membrane material in the experimental group had good sound conductivity, which was beneficial to postoperative hearing recovery.

[0150] Table 5. Hearing test results

[0151]

[0152] 8. HE staining

[0153] The tympanic membranes of the experimental group 2 were healed 12 weeks after surgery and HE staining sections were observed. Figure 6 As shown, Figure 6 The right part is an enlarged view of the local tympanic membrane where the left circle is located. After HE staining, it can be seen that the new tympanic membrane repaired 12 weeks after surgery has a three-layer structure of outer squamous epithelium, middle fibrous connective tissue and inner mucosa, which is not much different from the normal tympanic membrane.

[0154] The present invention has been specifically described above in conjunction with specific embodiments. These specific embodiments are only used for illustration and cannot be used to limit the scope of protection of the present invention. Those skilled in the art may make various modifications, changes or substitutions to the present invention without departing from the essence and scope of the present invention. Therefore, various equivalent changes made according to the present invention still belong to the scope covered by the present invention.

Claims

1. A method for preparing a sound-conducting biological tympanic membrane repair material, characterized in that: The method comprises the following steps: providing a spinning solution and a cross-linking solution, wherein the spinning solution comprises gelatin; The spinning solution and the cross-linking solution are formed into a spinning fiber membrane through an electrostatic spinning process; Wherein, the thickness of the spun fiber membrane is 50-400 μm, the cross-linking degree is 60%-90%, and the resonance frequency is 220 Hz -600 Hz; The electrospinning comprises an initial spinning section, a middle spinning section and a final spinning section, wherein the middle spinning section is between the initial spinning section and the final spinning section. In the initial stage of spinning, spinning is performed at a first spinning voltage to form a first fiber accumulation layer; In the middle stage of spinning, spinning is performed at a second spinning voltage to form a second fiber accumulation layer on the first fiber accumulation layer; In the final stage of spinning, spinning is performed at a third spinning voltage to form a third fiber accumulation layer on the second fiber accumulation layer; in, The first spinning voltage is less than the second spinning voltage, and the second spinning voltage is less than the third spinning voltage; The initial spinning time is shorter than the middle spinning time, and the final spinning time is shorter than the middle spinning time.

2. The preparation method according to claim 1, characterized in that The resonance frequency of the spun fiber membrane is 450 Hz to 600 Hz.

3. The preparation method according to claim 1, characterized in that: The elastic modulus of the spun fiber membrane is 19.2-45.3 MPa, and the tensile strength is 1.8-3.6 MPa.

4. The preparation method according to claim 3, characterized in that: The elastic modulus of the spun fiber membrane is 35-40 MPa, and the tensile strength is 2.5-3.1 MPa.

5. The preparation method according to claim 1, characterized in that: The first fiber accumulation layer has a loose fiber structure suitable for being separated from an electrospinning receiving device; The second fiber stacking layer has a fiber structure with sufficient tensile properties; The third fiber stacking layer has a porous structure suitable for the adhesion and ingrowth of epithelial cells and mucosal cells.

6. The preparation method according to claim 1, characterized in that: The first spinning voltage is 45-55 kV, the second spinning voltage is 55-60 kV, and the third spinning voltage is 60-65 kV.

7. The preparation method according to claim 1, characterized in that: The initial spinning period is 0.2-0.8h, the middle spinning period is 4.5-7h, and the final spinning period is 0.2-0.8h.

8. The preparation method according to claim 1, characterized in that: The gelatin is drug-modified gelatin, and the preparation of the drug-modified gelatin includes: chlorination treatment of the drug to form a chlorinated drug, and then mixing the chlorinated drug with gelatin to form the drug-modified gelatin.

9. The preparation method according to claim 8, characterized in that: The chloroacylation treatment is to react the drug with thionyl chloride.

10. The preparation method according to claim 8, characterized in that: The drug is selected from one or more of the following drugs: levofloxacin, ofloxacin, norfloxacin, pefloxacin, enoxacin and ciprofloxacin.

11. The preparation method according to claim 10, characterized in that: After chloracylation, the drug is linked to gelatin through an ester bond to form drug-modified gelatin.

12. The preparation method according to claim 1, characterized in that: The repair material degrades within 2-3 months.

13. A sound-conducting biological tympanic membrane repair material, characterized in that: The sound-conducting biological tympanic membrane repair material is made by the preparation method described in any one of claims 1-12.